Vol 25, No 6 (2020)
Original research articles
Published online: 2020-11-01

open access

Page views 344
Article views/downloads 474
Get Citation

Connect on Social Media

Connect on Social Media

Serum cytokine profile as a potential prognostic tool in colorectal cancer patients – one center study

Paulina Czajka-Francuz1, Tomasz Francuz2, Sylwia Cisoń-Jurek1, Aleksander Czajka3, Marcin Fajkis1, Bożena Szymczak1, Maciej Kozaczka4, Krzysztof Piotr Malinowski5, Wojciech Zasada6, Jerzy Wojnar1, Jerzy Chudek1
DOI: 10.1016/j.rpor.2020.08.004
Rep Pract Oncol Radiother 2020;25(6):867-875.

Abstract

Aim

Comparison of 14 cytokines levels between a control group and prospectively enrolled CRC patients to confirm their significance in CRC development. We tested if a model based on 14 cytokines levels could predict prognosis in Caucasian CRC patients treated with 5-FU based chemotherapy.

Background

Novel prognostic tools in colorectal cancer (CRC) are necessary to optimize treatment, reduce toxicity and chemotherapy (CHT) costs.

Materials and Methods

We assessed prognostic significance of 14 cytokines: IL-1 beta, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL-17A in 75 prospectively enrolled CRC patients before initiation of palliative or adjuvant CHT and in 22 control subjects. Readings were taken using the Bio-Plex 200 System. Response to treatment was assessed after 6 months from initiation of CHT. The treated group was divided depending on the response into a progressors (death, progression of disease) and non-progressors group (stable disease, partial response, complete response).

Results

We found that increased concentration of IL-8 was a negative prognostic factor in the whole group and palliative subgroup, whereas increased level of IL-10, IL-7, and IL-12p70 was a negative predictor in the adjuvant group CHT.

Conclusions

We proposed a statistical model based on circulating cytokine levels, showing a good prognostic value in prediction of the response to CHT (AUC = 0.956). The model, including combined IL-2, IL-8, IL-10 and IL-13 levels, established in the whole treated group, should be validated in larger trials.

Article available in PDF format

View PDF Download PDF file



Reports of Practical Oncology and Radiotherapy